ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 228 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $877,716 | -81.8% | 19,027 | -84.2% | 0.00% | -83.3% |
Q1 2023 | $4,831,007 | +21.5% | 120,474 | +40.4% | 0.02% | +9.1% |
Q4 2022 | $3,976,689 | +442.5% | 85,834 | +385.1% | 0.02% | +450.0% |
Q3 2022 | $733,000 | -61.6% | 17,695 | -32.7% | 0.00% | -63.6% |
Q1 2022 | $1,910,000 | -52.5% | 26,295 | -45.0% | 0.01% | -50.0% |
Q4 2021 | $4,021,000 | +279.3% | 47,816 | +306.8% | 0.02% | +214.3% |
Q3 2021 | $1,060,000 | -60.9% | 11,754 | -58.7% | 0.01% | -63.2% |
Q2 2021 | $2,713,000 | +417.7% | 28,456 | +518.3% | 0.02% | +375.0% |
Q1 2021 | $524,000 | -67.3% | 4,602 | -60.3% | 0.00% | -69.2% |
Q4 2020 | $1,604,000 | +82.7% | 11,585 | +8.5% | 0.01% | +85.7% |
Q3 2020 | $878,000 | -5.0% | 10,681 | -50.6% | 0.01% | -61.1% |
Q4 2019 | $924,000 | -34.9% | 21,635 | +17.1% | 0.02% | -52.6% |
Q2 2018 | $1,420,000 | – | 18,470 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |